High-risk Screenings for Fabry Among Chronic Kidney Disease Patients Should Use Biomarkers Other Than Gb3, Study Says
High-risk screenings for Fabry disease among individuals with chronic kidney disease (CKD) should be based on biomarkers other than globotriaosylceramide (Gb3) to lower the frequency of false positives, a study has found. Alternatively, according to the researchers, the normal range of urinary Gb3 values for patients…